Is Bristol-Myers Squibb Company (BMY) Undervalued?
Based on the current stock price of $54.64 and a P/E ratio of 18.40,Bristol-Myers Squibb Company has a PEG ratio of 0.04.
The Short Answer:
Most analysts consider a PEG ratio below 1.0 to be undervalued. With a ratio of 0.04, BMY appears to be potentially undervalued relative to its growth rate of 468.65%.
Based on a PEG ratio of 0.04 (adjusted for dividends).
Compare BMY vs Competitors
Use the calculator below to see how BMY stacks up against other stocks in the same industry.
How we analyzed BMY
We calculated the PEG (Price/Earnings-to-Growth) ratio by taking the Price-to-Earnings Ratio of 18.40and dividing it by the annual growth rate of 468.65%.
PEG = 18.40 (P/E) ÷ 468.65 (Growth) = 0.04
Frequently Asked Questions about BMY
What is the current PEG Ratio for Bristol-Myers Squibb Company (BMY)?+
The current PEG Ratio for Bristol-Myers Squibb Company is 0.04. A PEG ratio below 1.0 generally suggests the stock may be undervalued relative to its growth.
Is BMY stock undervalued right now?+
Based on the PEG ratio of 0.04, Bristol-Myers Squibb Company appears to be potentially undervalued. Investors typically look for a PEG ratio below 1.0 to find undervalued growth stocks.
What is the PEGY Ratio for BMY?+
The PEGY ratio for Bristol-Myers Squibb Company is 0.04. This metric accounts for dividend yield (4.61%), providing a more complete valuation picture.